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Background-—Heart failure is one of the most important late effects after treatment for cancer in childhood. The goals of this study
were to evaluate the risk of heart failure, temporal changes by treatment periods, and the risk factors for heart failure in childhood
cancer survivors (CCS).
Methods and Results-—The DCOG-LATER (Dutch Childhood Oncology Group–Long-Term Effects After Childhood Cancer) cohort
includes 6,165 5-year CCS diagnosed between 1963 and 2002. Details on prior cancer diagnosis and treatment were collected for
this nationwide cohort. Cause-speciﬁc cumulative incidences and risk factors of heart failure were obtained. Cardiac follow-up was
complete for 5,845 CCS (94.8%). After a median follow-up of 19.8 years and at a median attained age of 27.3 years, 116 survivors
developed symptomatic heart failure. The cumulative incidence of developing heart failure 40 years after childhood cancer
diagnosis was 4.4% (3.4%–5.5%) among all CCS. The cumulative incidence of heart failure grade ≥3 among survivors treated in the
more recent treatment periods was higher compared with survivors treated earlier (Gray test, P=0.05). Mortality due to heart failure
decreased in the more recent treatment periods (Gray test, P=0.02). In multivariable analysis, survivors treated with a higher dose
of mitoxantrone or cyclophosphamide had a higher risk of heart failure than survivors who were exposed to lower doses.
Conclusions-—CCS treated with mitoxantrone, cyclophosphamide, anthracyclines, or radiotherapy involving the heart are at a high
risk for severe, life-threatening or fatal heart failure at a young age. Although mortality decreased, the incidence of severe or life-
threatening heart failure increased with more recent treatment periods. ( J Am Heart Assoc. 2019;8:e009122. DOI: 10.1161/
JAHA.118.009122)
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C hildhood cancer 5-year survival rates have improvedconsiderably, from 20% in the 1940s1 to 70% to 80% at
present.2 It is well established that (childhood) cancer
treatments can induce chronic health conditions in childhood
cancer survivors (CCS).3–5 As a result of better survival over
the years, the survivor population continues to grow in size. It
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is known that 75% of CCS will develop at least a chronic
health condition,4 and among those aged 45 years, 80.5% of
survivors will have a serious/disabling or life-threatening
health condition.5
Heart failure is one of the most frequent late effects in
CCS, contributing to signiﬁcant morbidity and mortality.3–9
Previous reports show that the cumulative incidence of
symptomatic heart failure among CCS 30 years after diagno-
sis ranges between 2.7% and 4.1%.10,11 The prevalence of
asymptomatic heart failure, deﬁned as a left ventricular
shortening fraction <30%, has been found to be 27% in CCS
treated with cardiotoxic treatment at a median of 15 years
after diagnosis.12
A higher dose of anthracyclines and radiotherapy involving
the heart region are associated with asymptomatic and
symptomatic heart failure.10,11,13–18 So far, the role of other
types of chemotherapy such as mitoxantrone and cyclophos-
phamide on heart failure risk is not clear.11,19
The risk of cardiotoxicity after childhood cancer treatment
has already been known for several decades. Studies that
investigate the temporal changes of heart failure by treatment
periods are lacking. Recent studies did show a reduction in
cardiac mortality of CCS in later periods of treatment
compared with earlier treatment periods.8,9
We aimed to determine the cumulative incidence, the
temporal changes by treatment period, and factors that are
associated with the cause-speciﬁc incidence of systematically
ascertained and validated symptomatic heart failure in CCS
within a Dutch nationwide cohort. This knowledge will guide
future treatment and surveillance protocols for children with
cancer.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
We obtained our study population from the national DCOG-
LATER (Dutch Childhood Oncology Group—Long-Term Effects
After Childhood Cancer) nationwide cohort (n=6165), a
collaborative effort of all Dutch pediatric oncology/hematol-
ogy centers. Eligible survivors included 5-year CCS diagnosed
before the age of 18 years between January 1, 1963 and
December 31, 2001 with a malignancy according to the third
edition of the International Classiﬁcation of Childhood
Cancer.20 We only included CCS who were living in the
Netherlands at the time of childhood cancer diagnosis and
who were treated in 1 of the Dutch pediatric oncology/
hematology centers (Academic Medical Center Amsterdam,
VU University Medical Center, Leiden University Medical
Center, Erasmus Medical Center, University Medical Center
Groningen, Radboudumc, and University Medical Center
Utrecht).
Data Collection on Chemotherapy Treatment
Data on childhood cancer diagnosis and treatment (including
treatment for recurrences) were extracted from the medical
records for all eligible CCS. The total cumulative anthracycline
dose was calculated by summing the doxorubicin-equivalent
doses (daunorubicin [90.45]21, epirubicin [90.67], idarubicin
[93]) based on the previously published equivalence ratio.22
This cumulative anthracycline dose (the sum of all types of
anthracyclines) was based directly on risk for heart failure and
not on those doses that produce equivalent hematological
toxicity with the assumption that hematological and cardiac
toxicities are correlated.21
Data Collection on Radiotherapy Treatment
Detailed radiotherapy involving the heart was classiﬁed as
follows: no radiotherapy involving the heart; radiotherapy
potentially involving the heart (abdomen, para-aortal,
spleen, inverted Y, spine not otherwise speciﬁed, scapula,
Clinical Perspective
What Is New?
• In a nationwide cohort of 6165 5-year childhood cancer
survivors, we observed an increase in cumulative incidence
of severe or life-threatening heart failure in recent treatment
periods (compared with earlier periods); a dose-response
relation of mitoxantrone and an association of cyclophos-
phamide with symptomatic heart failure were observed.
These results should be replicated in a larger cohort.
What Are the Clinical Implications?
• As the current cohort study demonstrates, childhood cancer
survivors treated with cardiotoxic treatment have a high risk
of developing heart failure at a relatively young age.
• Therefore, it may be worthwhile to be vigilant of symptoms
that suggest cardiac dysfunction/heart failure in adolescent
and young adult childhood cancer survivors, even decades
after initial treatment.
• Other treatment possibilities, if available, should be consid-
ered in childhood cancer treatment protocols, and car-
diotoxic doses should be limited because heart failure also
develops after low doses of anthracyclines and/or mitox-
antrone.
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vertebrae, ribs/sternum/clavicle, kidney, liver, total abdom-
inal radiation); radiotherapy involving the heart (total body
radiation, thorax, mediastinum, total node, mantle ﬁeld,
spine [whole and thoracic], lung, parasternal). We used the
maximum prescribed dose of the largest ﬁeld involving the
heart and added the dose of total body radiation. For
the latter group, we used a cutoff point of 20 Gy, which is
the median of the cumulative prescribed dose. Validation
of radiotherapy data was performed by experts in radio-
therapy.
Cardiac Outcome Data Collection and Cardiac
Follow-Up
The outcome of interest was heart failure, graded according to
the Common Terminology Criteria for Adverse Events as grade
3 (severe), 4 (life-threatening), or 5 (death).23 The incidence
date of heart failure was deﬁned as the date of an abnormal
diagnostic test combined with symptoms.
Information on potential heart failure was collected from 3
different data sources: the DCOG-LATER questionnaire, GP
(primary physician) DCOG-LATER questionnaire, and medical
records (Figure S1). Cohort members resident in the Nether-
lands received a DCOG-LATER questionnaire between 2012
and 2014. The DCOG-LATER questionnaire is a general health
and risk factor questionnaire including diseases of the
circulatory system. To optimize response, CCS initially not
willing to participate were offered the option of completing a
brief telephone survey addressing sociodemographic charac-
teristics and health status. CCS were considered nonrespon-
ders to the DCOG-LATER questionnaire if they had not
responded after a written invitation, a written reminder, and
at least 2 telephone reminders. For nonresponders, we
obtained data on heart failure from the GP DCOG-LATER
questionnaire, a short questionnaire on major health out-
comes and risk factors sent to the GP of the CCS. The GP was
considered a “GP nonresponder” if he or she had not
responded after a written invitation, a written reminder, and
at least 2 telephone reminders. For “GP nonresponders,” we
extracted heart failure data from the DCOG-LATER outpatient
clinics where available. Finally, for known deceased CCS, the
main cause of death and underlying diseases were extracted
from the medical records. Potential heart failure was subse-
quently validated following a standardized method described
previously (Figure S2 and Data S1 for more detailed
information).24
For the DCOG-LATER questionnaire data, written informed
consent was obtained from the participating survivors.
Informed consent was also sought from the parents of
underage (<18 years of age) CCS. Data collection from the GP
DCOG-LATER questionnaire and medical records was exempt
from institutional review board review.
Statistical Analyses
The following dates were assigned as the end of cardiac
follow-up: the date of death for decedents; the date of DCOG-
LATER (or GP DCOG-LATER) questionnaire completion for
responders; the date of the last recorded patient contact for
nonresponders or for CCS lost to follow-up. If a cohort
member died from a cause other than heart failure, death was
considered a competing event.25 Heart failure was evaluated
if it started more than 5 years after childhood cancer
diagnosis or if it started within 5 years of childhood cancer
diagnosis and was still present after 5 years from diagnosis.
The time at risk started 5 years after childhood cancer
diagnosis, and it ended on the incidence date of heart failure
diagnosis or at the end date of cardiac follow-up, whichever
occurred ﬁrst.
Cumulative Incidence
We estimated the cumulative incidence overall and for
different mutually exclusive treatment groups using the
nonparametric Aalen-Johansen estimator. Both follow-up time
since childhood cancer diagnosis and age at follow-up were
used as time scales. Additionally, we examined the cumulative
incidence of heart failure (grades 3, 4, and 5) in relation to the
period of treatment (1970–1979, 1980–1989, and 1990–
2001). The differences between the groups were evaluated
with Gray log-rank tests.26 We also tested the differences
between the period of treatment and the use of anthracycli-
nes (yes versus no), anthracycline dose, mitoxantrone (yes
versus no), mitoxantrone dose, and radiotherapy to the chest.
Risk Factor Analyses
We assessed risk factors for heart failure using a multivariable
Cox proportional hazards model with attained age as the time
scale. The model was adjusted for age at childhood cancer
diagnosis, sex, and calendar year of childhood cancer
diagnosis. We examined possible risk factors for heart failure
based on the literature and clinical knowledge. We evaluated
the effects of age at diagnosis, sex, and year of cancer
diagnosis as well as the effect of treatment: anthracycline (per
1 mg/m2), mitoxantrone (per 1 mg/m2), cyclophosphamide
(per 100 mg/m2), cisplatin (per 1 mg/m2), ifosfamide (per
1 mg/m2), vincristine (per 1 mg/m2), and radiotherapy
involving the heart (no radiotherapy involving the heart;
radiotherapy potentially involving the heart; radiotherapy
involving the heart <20 Gy; radiotherapy involving the heart
≥20 Gy). We examined the dose-response relationship
between anthracyclines, mitoxantrone, and cyclophos-
phamide and the development of heart failure by modeling
via restricted cubic splines using 3 knots (10%, 50%, 90%
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quantiles). In order to avoid overadjusting the model, we did
not include treatment and diagnosis variables in the same
model.
Two-sided P-values were reported, and those of less than
0.05 were considered statistically signiﬁcant. Analyses were
performed using R (version 3.1.1; R Foundation, Vienna,
Austria) and SPSS (version 24; IBM SPSS Statistics, Armonk,
NY).
Results
Study Population, Cardiac Follow-Up, and Cardiac
Events
The nationwide cohort included 6165 CCS. For 5845 CCS
(94.8%), cardiac follow-up information was retrieved. Of those
5845 CCS, cardiac follow-up was complete for 84.7% in
2013. Data S2 and Figure S1 provide an extensive overview
of the cardiac follow-up. Table 1 presents demographic
information, tumor characteristics, and follow-up information
on the cohort with cardiac follow-up and CCS with heart
failure. At the end of follow-up 5278 (90.3%) CCS were alive,
and 567 (9.7%) were deceased. Median follow-up time since
childhood cancer diagnosis was 19.9 years (range 5.0–
50.4 years), and median attained age was 27.3 years (range
5.1–65.2 years).
Among the 5845 eligible CCS with cardiac follow-up, 116
CCS (2.0%) developed heart failure, 61 CCS were grade 3, 33
CCS grade 4, and 22 CCS grade 5. Among all cases, 35
(30.2%) had received both cardiotoxic chemotherapy and
radiotherapy involving the heart, 75 (64.7%) had received
cardiotoxic chemotherapy only, 2 cases (1.7%) had received
radiotherapy involving the heart only, and the 4 remaining
cases (3.4%) had received no known potential cardiotoxic
treatment, or their treatment was unknown.
The 3 cases without known potential cardiotoxic treatment
had conditions known to predispose to heart failure:
Duchenne muscular dystrophy, noncompaction cardiomyopa-
thy, and Tetralogy of Fallot. The details of the CCS with heart
failure are presented in Table 1.
Cumulative Incidence by Treatment Groups
Table S1 presents the cumulative incidence of developing
heart failure by time since childhood cancer diagnosis and
for mutually exclusive treatment groups. The cumulative
incidence of developing heart failure 40 years after child-
hood cancer diagnosis was 4.4% (95% CI 3.4% to 5.5%). The
cumulative incidence of heart failure 40 years after diagnosis
was much higher among CCS who received had 1 or more
types of cardiotoxic treatment (10.6%, 95% CI 7.4% to 13.9%)
than among CCS treated without cardiotoxic treatment
(0.3%, 95% CI 0.0% to 0.7%) (Gray test of cardiotoxic
treatment versus no cardiotoxic treatment, P<0.0001)
(Table S1 and Figure 1). The cumulative incidence of heart
failure 40 years after diagnosis was 27.8% (95% CI 5.1% to
50.6%) for CCS who had received both cardiotoxic
chemotherapy and radiotherapy involving the heart, 10.5%
(95% CI 6.4% to 14.4%) for CCS who had received only
cardiotoxic chemotherapy, and 3.0% (95% CI 0.0% to 5.9%)
for CCS treated with only radiotherapy involving the heart
(Table S1, Figure S3).
The cumulative incidence of heart failure 20 years after
diagnosis for CCS treated with mitoxantrone (anthracycli-
nes) was 11.4% (95% CI 3.6% to 19.1%). The cumulative
incidence increased signiﬁcantly in the CCS treated with
higher anthracycline doses (Table S1 and Figure 2).
The cumulative incidence of developing heart failure by
attained age is presented in Table S2 and Figure S4. At age
50 years, the cumulative incidence of developing heart failure
in the whole cohort was 5.3% (95% CI 3.7% to 6.9%).
Cumulative Incidence by Treatment Era
Table 2 shows the cardiotoxic treatment survivors received
for the different treatment periods (1960–1979, 1980–1989,
and 1990–2001). We observed a statistically signiﬁcant
difference between survivors treated in the oldest treatment
era (1960–1979) and in more recent treatment eras (1980–
1989 and 1990–2001), especially for those survivors treated
with anthracyclines (compared with those not treated with
anthracyclines), and for those survivors treated with radio-
therapy to the chest.
The cumulative incidence of heart failure (grades 3, 4, and
5) increased for CCS treated in more recent years (Fig-
ure 3A). The cumulative risks at 20 years after diagnosis for
CCS treated during 1970–1979, 1980–1989, and 1990–
2001 were 0.5% (95% CI 0.01% to 0.9%), 1.6% (95% CI 1.0%
to 2.2%), 1.5% (95% CI 0.9% to 2.0%), respectively. The risks
of heart failure 20 years after diagnosis for CCS treated
during 1990–2001 and between 1980 and 1989 were
signiﬁcantly higher than the risk of heart failure for CCS
treated during 1970–1979 (Gray test 1970–1979 versus
1980–1989, P=0.01; 1970–1979 versus 1990–2001,
P=0.03). Figure 3B displays the cumulative incidence per
treatment period for fatal heart failure (grade 5). The risks of
a fatal event 20 years after diagnosis for CCS treated during
1970–1979 and 1980–1989 were signiﬁcantly higher than
the risk of CCS treated during 1990–2001 (Gray test 1970–
1979 versus 1990–2001, P=0.04; 1980–1989 versus 1990–
2001, P=0.02). Because most childhood cancer treatment
centers started in 1970 in the Netherlands, there is a
possibility that children had been treated in adult cancer
centers before that time; thus, we excluded children
DOI: 10.1161/JAHA.118.009122 Journal of the American Heart Association 4
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Table 1. Patient, Cancer, and Treatment Characteristics of the 5-Year Survivors of the DCOG-LATER Cohort With Complete
Cardiac Follow-Up
Characteristics
Cohort With Cardiac Follow-Up (n=5845)
(94.8%)*
CCS With Heart Failure
(n=116)
n (%) n (%)
Patient characteristics
Sex
Female 2588 (44.3) 44 (37.9)
Male 3257 (55.7) 72 (62.1)
Cancer characteristics
Primary childhood cancer (ICCC)
Leukemias, myeloproliferative diseases, and myelodysplastic diseases 2034 (34.8) 30 (25.9)
Lymphomas and reticuloendothelial neoplasms 1019 (17.4) 26 (22.4)
CNS and miscellaneous intracranial and intraspinal neoplasms 749 (12.8) 3 (2.6)
Neuroblastoma and other peripheral nervous cell tumors 306 (5.2) 2 (1.7)
Retinoblastoma 29 (0.5) 0 (0)
Renal tumors 571 (9.8) 11 (9.5)
Hepatic tumors 46 (0.8) 0 (0)
Bone tumors 355 (6.1) 25 (21.6)
Soft tissue and other extraosseous sarcomas 422 (7.2) 18 (15.5)
Germ cell tumors, trophoblastic tumors, and neoplasms of gonads 219 (3.7) 0 (0)
Other malignant epithelial neoplasms and malignant melanomas 88 (1.5) 1 (0.9)
Other and unspecified malignant neoplasms 7 (0.1) 0 (0)
Age at diagnosis (y), median (IQR) 5.5 (2.8–10.5) 6.1 (2.8–10.5)
0 to 4 2692 (46.1) 49 (42.2)
5 to 9 1567 (26.8) 35 (30.2)
10 to 14 1233 (21.1) 28 (24.1)
15 to 17 353 (6.0) 4 (3.4)
Treatment period
1963 to 1979 990 (16.9) 22 (19.0)
1980 to 1989 1853 (31.7) 58 (50.0)
1990 to 2001 3002 (51.4) 36 (31.0)
Overall treatment modality
Surgery only 587 (10.0) 0 (0)
ChemotherapySurgery 2882 (49.3) 60 (51.7)
RadiotherapySurgery 445 (7.6) 0 (0)
Chemotherapy and RadiotherapySurgery 1854 (31.7) 55 (47.4)
No therapy/unknown 77 (1.3) 1 (0.9)
Cardiotoxic treatment
No cardiotoxic treatment 2845 (48.7) 3 (2.6)
Cardiotoxic CT only 2304 (39.4) 83 (71.6)
RT involving the heart only 211 (3.6) 4 (3.4)
Cardiotoxic CT and chest RT 434 (7.4) 25 (21.6)
Unknown 51 (0.9) 1 (0.9)
Continued
DOI: 10.1161/JAHA.118.009122 Journal of the American Heart Association 5


















 http://ahajournals.org by on March 18, 2019
Table 1. Continued
Characteristics
Cohort With Cardiac Follow-Up (n=5845)
(94.8%)*
CCS With Heart Failure
(n=116)
n (%) n (%)
Anthracyclines median dose (IQR) 175 (114–272) 360 (201–450)
No anthracyclines 3099 (53.0) 13 (11.2)
1 to 100 mg/m2 491 (8.4) 21 (18.1)
100 to 250 mg/m2 1402 (24.0) 33 (28.4)
>250 mg/m2 720 (12.3) 42 (36.2)
Missing 133 (2.3)† 7 (6.0)
Mitoxantrone median dose (IQR) 40 (20–60) 45 (20–120)
No mitoxantrone 5660 (96.8) 103 (88.8)
<40 mg/m2 81 (1.4) 6 (5.2)
>40 mg/m2 58 (1.0) 6 (5.2)
Missing 46 (0.7)‡ 1 (0.9)
Cyclophosphamide (intravenous)
None 3674 (62.8) 34 (29.3)
Any 2132 (36.5) 81 (69.8)
Unknown 39 (0.7) 1 (0.9)
Cisplatin
None 5363 (91.8) 103 (88.8)
Any 443 (7.6) 12 (10.3)
Unknown 39 (0.7) 1 (0.9)
Ifosfamide
None 5107 (87.4) 98 (84.5)
Any 699 (12.0) 17 (14.7)
Unknown 39 (0.7) 1 (0.9)
Vincristine
None 1642 (28.1) 16 (13.8)
Any 4164 (71.2) 99 (85.3)
Unknown 39 (0.7) 1 (0.9)
Radiotherapy field involving the heart
No chest radiotherapy 4575 (78.3) 78 (67.2)
Radiotherapy potentially involving the heart 588 (10.1) 9 (7.8)
Radiotherapy involving the heart <20 Gy 275 (4.7) 15 (12.9)
Radiotherapy involving the heart ≥20 Gy 363 (6.2) 14 (12.1)
Unknown 44 (0.7) 0 (0)
Recurrence
No 4836 (82.7) 87 (75.0)
Yes 1009 (17.3) 29 (25.0)
Follow-up
Vital status
Alive 5278 (90.3) 87 (75.0)
Deceased 567 (9.7) 29 (25.0)
Continued
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diagnosed with cancer before 1970 (n=90, 1.5%; n=2
children treated with anthracyclines).
Risk Factor Analyses
Table 3 presents the results of the multivariable model for the
analysis of risk factors for heart failure (grade 3, 4, and 5). We
found that younger age at childhood cancer diagnosis (per-year
hazard ratio [HR]=0.8, 95% CI 0.8–0.9), more recent year of
childhood cancer diagnosis (HR=1.0, 95% CI 1.0–1.1),
anthracyclines (per 1 mg/m2), mitoxantrone (per 1 mg/m²),
cyclophosphamide (per 100 mg/m²) (the dose-response curves
and the actual HRs for anthracyclines, mitoxantrone, and
cyclophosphamide are presented in Figure 4), and radiotherapy
involving the heart (HR=2.0, 95% CI 1.1–3.6; HR=2.1, 95% CI
1.1–4.0) were signiﬁcantly associated with heart failure risk.
There was no inﬂuence of sex on the risk of developing heart
failure. We did not ﬁnd any statistically signiﬁcant interaction
between radiotherapy to the chest and cardiotoxic chemother-
apy or among the different chemotherapy treatments.
Table 1. Continued
Characteristics
Cohort With Cardiac Follow-Up (n=5845)
(94.8%)*
CCS With Heart Failure
(n=116)
n (%) n (%)
Attained age (y), median (min-max) 27.3 (5.1–65.2) 23.8 (6.2–48.8)
≤14 463 (7.9) 15 (12.9)
15 to 24 1949 (33.4) 45 (38.8)
25 to 34 2000 (34.2) 38 (32.8)
35 to 44 1129 (19.3) 16 (13.8)
45 to 54 267 (4.6) 2 (1.7)
≥55 37 (0.6) 0 (0)
Follow-up duration from primary cancer diagnosis (y), median (min-max) 19.9 (5.0–50.4) 16.8 (5.0–36.8)
>5 to 9 480 (8.2) 21 (18.1)
19 to 10 2459 (42.1) 48 (41.4)
20 to 29 1791 (30.6) 34 (29.3)
30 to 39 965 (16.5) 13 (11.2)
≥40 150 (2.6) 0 (0)
Source
LATER questionnaire 3056 (52.3) 58 (50.0)
General practitioner questionnaire 773 (13.2) 6 (5.2)
Medical chart 2016 (34.5) 52 (44.8)
Cardiac events
Type of validated symptomatic heart failure
Grade 3 61 (52.5) 61 (52.5)
Grade 4 33 (28.5) 33 (28.5)
Grade 5 22 (19.0) 22 (19.0)
Other cardiac events
Cardiac ischemia 21 (0.4) 2 (1.7)§
Pericarditis 13 (0.2) 1 (0.9)§
Valvular disease 22 (0.4) 3 (2.6)§
Arrhythmia 41 (0.7) 3 (2.6)§
CCS indicates childhood cancer survivor; CNS, central nervous system; CT, chemotherapy; DCOG-LATER, Dutch Childhood Oncology Group Long-term outcomes after cancer treatment;
ICCC, International Classiﬁcation of Childhood Cancer; IQR, interquartile range; RT, radiatiotherapy.
*Percentage of the total DCOG-LATER cohort.
†n=94 anthracycline=yes, but dose missing.
‡n=7 mitoxantrone=yes, but dose missing.
§Cardiac event before the onset of heart failure.
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Discussion
CCS are at a high risk of developing heart failure in young
adulthood after cardiotoxic treatment. Important ﬁndings of
this study are the increase in cumulative incidence of severe
or life-threatening heart failure in more recent treatment
periods and the association of mitoxantrone and cyclophos-
phamide with symptomatic heart failure.
The current cohort study demonstrates that CCS treated
with cardiotoxic treatment have a high risk of developing
heart failure even at a relatively young age.
Previous research showed a reduction in (cardiac) mortality
among CCS in recent periods of treatment, and the authors
attributed this to a reduction in anthracycline dose in
treatment regimens.8,9 In line with this ﬁnding, our study
identiﬁed a decreased risk of mortality due to heart failure in
more recent treatment eras.
In our study we also identiﬁed an increased risk of heart
failure with a broader deﬁnition (severe, life threatening, and
death due to heart failure) and a decreased risk of heart failure
(fatal) for CCS treated in more recent treatment years
compared with survivors treated earlier. We identiﬁed this
higher risk in the comparisons of the cumulative risk estimates
as well as in the Cox proportional hazards model analysis. The
cumulative incidence of heart failure remained low with
anthracyclines at doses below 100 mg/m2, or at least below
250 mg/m2. However, most importantly, our results showed
no safe dose for anthracyclines. This ﬁnding and the statis-
tically signiﬁcant association and dose-response relationship
of mitoxantrone with symptomatic heart failure underscore the
need for primary prevention (such as avoiding cardiotoxic
treatment), the use of lower doses of cardiotoxic treatments in
children with cancer, and considering alternatives to mitox-
antrone in new treatment protocols for children with cancer.
Several explanations for the increased risk of heart failure
in more recent treatment periods can be considered. A ﬁrst
explanation could be the more frequent use of cardiotoxic
treatment. The number of CCS treated with anthracyclines
and mitoxantrone increased over the decades (Table 2).
Another possible explanation for the increased risk of heart
failure amongCCS treatedmore recently could be that CCSwith
heart failure in recent eras were diagnosed more precisely.
Specialized outpatient late-effects clinics were ﬁrst established
during the decade from 1990 to 2000, and among physicians,
awareness of anthracycline-induced heart failure increased. A
third reason for the increased risk of heart failure over time
could be a decrease in cardiac mortality. Individuals with
Figure 1. Cumulative incidence of heart failure for cardiotoxic
treatment (anthracyclines, mitoxantrone, and radiotherapy involv-
ing the heart) with time since childhood cancer diagnosis as time
scale. P-value for Gray test is P<0.0001. Shaded areas indicate
95% CI.
Figure 2. Cumulative incidence of heart failure (grades 3, 4, and
5) for 2 speciﬁc treatment groups: anthracyclines only (n=2598
cohort members, 96 cases) and mitoxantrone (with/without
anthracyclines) (n=146 cohort members, 12 cases). All childhood
cancer survivors who had radiotherapy involving the heart region
were excluded from these analyses. Parwise comparisons found
these degrees of signiﬁcance: no anthracycline/mitoxantrone vs
anthracycline 1 to 100 mg/m2, P=0.17; no anthracycline/mitox-
antrone vs anthracycline 100 to 250 mg/m2, P<0.00001; no
anthracycline/mitoxantrone vs anthracycline >250 mg/m2,
P<0.00001; no anthracycline/mitoxantrone vs mitoxantrone,
P<0.00001; anthracycline 1 to 100 mg/m2 vs anthracycline
100 to 250 mg/m2, P=0.007; anthracycline 1 to 100 mg/m2 vs
anthracycline >250 mg/m2, P<0.00001; anthracycline 1 to
100 mg/m2 vs mitoxantrone, P<0.00001; anthracycline 100 to
250 mg/m2 vs anthracycline >250 mg/m2, P<0.00001; anthra-
cycline 100 to 250 mg/m2 vs mitoxantrone, P<0.00001; anthra-
cycline >250 mg/m2 vs mitoxantrone, P=0.02. Shaded areas
indicate 95% CI.
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cardiac dysfunction are expected to be referred more often to
the cardiologist and are perhaps treated in an earlier phase.
Similarly, treatment of heart failure has improved considerably
over the past few decades.27 With the introduction of
angiotensin-converting enzyme inhibitors by the end of the
1980s28 into heart failure treatment and the addition of b-
blockers by the end of the 1990s,29 the mortality due to heart
failure signiﬁcantly decreased in the overall population of
patients with heart failure.30
Despite the small number of CCS treated with mitox-
antrone in our study, our results showed a statistically
signiﬁcant association of mitoxantrone with symptomatic
heart failure in our cohort of CCS with a dose-response
relationship. We showed this both in the comparisons of the
cumulative risk estimates—by time since treatment—as well
as in the Cox proportional hazards model analysis (with
attained age on the time scale and adjusted for follow-up
time). Our ﬁndings are in line with previous studies that have
described a mitoxantrone association with cardiac dysfunc-
tion and symptomatic heart failure in CCS.19,31 It has been
suggested that mitoxantrone has different cardiotoxic mech-
anisms from the anthracyclines.32,33 In the current study we
showed that timing of presentation for mitoxantrone-asso-
ciated heart failure seems different from that of anthracycline-
associated heart failure, and that there are differences with
respect to dose-response relationship. CCS treated with
mitoxantrone have a high risk for heart failure, and targeted
follow-up is needed.34 Further data on (childhood cancer)
patients treated with mitoxantrone need to be replicated in
studies with larger study populations. We found a signiﬁcant
association between cyclophosphamide and heart failure.
Acute cardiac damage from cyclophosphamide has been
suggested by other studies,35,36 but, to our knowledge, late
cardiac damage has not been previously reported. Further and
more extensive research into the role of cyclophosphamide in
the development of heart failure is needed.
Table 2. Description of Cardiotoxic Treatment for Different Cancer Treatment Periods
Treatment Between 1960 and 1979
(n=990 CCS)
Treatment Between 1980 and 1989
(n=1853 CCS)
Treatment Between 1990 and 2001
(n=3002 CCS)
Anthracycline
Median dose (IQR) 180 (22.5–740) 200 (18.0–1950) 160 (6.89–668)
n (%) n (%) n (%)
No anthracyclines 745 (75.2) 970 (52.3) 1384 (46.1)
Anthracyclines any dose 233 (23.6) 867 (46.8) 1607 (53.5)
Missing 12 (1.2) 16 (0.9) 11 (0.4)
1 to 100 mg/m2 75 (7.6) 174 (9.4) 212 (7.1)
100 to 250 mg/m2 40 (4.0) 324 (17.5) 1059 (35.3)
>250 mg/m2 85 (8.6) 342 (18.5) 302 (10.1)
Missing 33 (3.3) 27 (1.5) 34 (1.1)
Mitoxantrone
Median dose (IQR) 50 (20–40) 38 (22–46) 39 (20–70)
n (%) n (%) n (%)
No mitoxantrone 976 (98.5) 1822 (98.3) 2863 (95.4)
Mitoxantrone any dose 3 (0.3) 15 (0.8) 128 (4.3)
Missing 12 (1.2) 16 (0.9) 11 (0.4)
1 to 40 mg/m2 1 (33.4) 9 (60.0) 71 (55.5)
>40 mg/m2 2 (66.6) 3 (20.0) 53 (41.4)
Missing 3 (20.0) 4 (3.9)
Radiotherapy
No chest radiotherapy 650 (65.6) 1447 (78.1) 2478 (82.5)
Radiotherapy potentially involving
the heart
192 (19.4) 190 (10.3) 206 (6.9)
Radiotherapy involving the heart 142 (14.3) 204 (11.0) 301 (10.0)
Missing 7 (0.7) 11 (0.6) 17 (0.6)
CCS indicates childhood cancer survivor; IQR, interquartile range.
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The ﬁndings of this study need to be considered subject to the
limitation of not having information on the absorbed radiation
dose to the heart. However, based on the current results and
those reported previously,11 the association between radiother-
apy involving the heart and heart failure is less strong than the
association between chemotherapy and heart failure.
The strengths of the current study include the near
complete follow-up (94.8%, 84.7% until 2013) of our entire
nationwide cohort of CCS, the nearly complete collection of
treatment data, and the validation of all cases of heart failure
by extracting information from the medical charts or from the
treating physicians using an extraction-ﬂowchart method.24
These strengths will increase the validity of the study.
Our study ﬁndings can inform new treatment protocols for
children with cancer. In addition, other treatment options—if
available—should be considered in current childhood cancer
treatment protocols, and cardiotoxic doses should be limited
because heart failure also develops after low doses of
anthracyclines and/or mitoxantrone.
It is also important to realize that the risk of heart failure is
high even at a young attained age, and therefore, CCS at risk
of heart failure might beneﬁt from early intervention. Previous
literature suggests that early treatment can lead to better
survival in comparable study populations.37 Thus, our results
also warrant the need for appropriate cardiac surveillance of
CCS and can therefore inform the current recommendations34
for cardiomyopathy surveillance by suggesting the need to
provide separate recommendations for survivors treated with
mitoxantrone and anthracyclines.
In addition, future studies are needed to evaluate risk
factors models for heart failure that include variables that
Figure 3. A, Cumulative incidence of heart failure (grades 3, 4,
and 5) per treatment period, with time since childhood cancer
diagnosis. P-value for Gray test: 1970–1979 vs 1980–1989,
P=0.011; 1970–1979 vs 1990–2001, P=0.03; 1980–1989 vs
1990–2001, P=0.81 B, Cumulative incidence of heart failure
grade 5, fatal events, per treatment period with time since
childhood cancer diagnosis. P-value for Gray test: 1970–1979 vs
1980–1989, P=0.99; 1970–1979 vs 1990–2001, P=0.04; 1980–
1989 vs 1990–2001, P=0.02. All childhood cancer survivors
diagnosed between 1970 and 2001 were included in this ﬁgure.
Table 3. Multivariable Cox Proportional Hazard Regression Model for the Analysis of Potential Determinants for Heart Failure
(Grades 3, 4, 5): Age at Diagnosis, Sex, Period of Treatment, and Cancer Treatment
Covariates* REF (n)/Total (n) Hazard Ratio, Median (IQR) P Value REF (n)/Events (n)
Age at primary childhood diagnosis (per y) 0.8 (0.8–0.9) <0.001
Sex (REF=male) 3257/5845 0.9 (0.6–1.3) 0.64
Year of childhood cancer diagnosis (per y) 1.0 (1.01–1.1) 0.04
Anthracycline (per 1 mg/m2, splines) See Figure 4 <0.001
Mitoxantrone (per 1 mg/m2, splines) See Figure 4 <0.001
Cyclophosphamide (per 100 mg/m2, splines) See Figure 4 0.04
Chest radiotherapy
No chest radiotherapy 4575/5845 REF 78/116
Radiotherapy potentially involving the heart 588/5845 1.0 (0.4–2.0) 0.96 9/116
Radiotherapy involving the heart <20 Gy 275/5845 2.0 (1.1–3.6) 0.02 15/116
Radiotherapy involving the heart ≥20 Gy 363/5845 2.1 (1.1–4.0) 0.02 14/116
Cisplatin (per 1 mg/m2) 1.0 (1.0–1.0) 0.61
Ifosfamide (per 1 mg/m2) 1.0 (1.0–1.0) 0.28
Vincristine (per 1 mg/m2) 1.0 (1.0–1.0) 0.20
REF indicates reference category.
*We did not ﬁnd a signiﬁcant interaction term between anthracycline and radiotherapy involving the heart.
The bold values indicate the signiﬁcant risk factors.
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change value over time, such as smoking history, current BMI,
and presence of other heart diseases.
In conclusion, CCS are at high risk of developing severe
life-threatening or fatal heart failure even 40 years after their
diagnosis at a relatively young age, and CCS treated with
anthracyclines and mitoxantrone are most at risk. Although
mortality due to heart failure decreases in more recent
treatment periods, the incidence of severe or life-threatening
heart failure increases. Primary prevention to diminish the risk
of heart failure for CCS is needed.38
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Definition of Cardiac Event 
 
Childhood cancer survivor (CCS) had potentially heart failure if “yes” was answered 
to one of the following questions of the DCOG-LATER (Dutch Childhood Oncology 
Group - Long term Effects after Childhood Cancer) questionnaire: “Do you have now 
or did you ever have one of the following conditions, if yes please estimate at what 
age it started and if you use medications at this moment: heart attack, chest pain, 
valvular disease, inflammation of the sac around your heart (pericarditis), weak heart 
muscle (cardiomyopathy), heart failure, arrhythmias/ palpitations, other heart 
disease?”; “Did you ever have one of the following surgeries: replacement of the 
heart valve, other surgery to the heart (including stenting), did you ever have a 
pacemaker or ICD?”.  
When using the GP (general practitioner) DCOG-LATER questionnaire, we 
considered CCS to have potentially heart failure when “yes” was answered to one of 
the following questions: ”Did the CCS develop one of the following conditions since 
the diagnosis of the primary childhood cancer: arrhythmia, valvular disease, cardiac 
conduction disorders, angina, ischemia or infarction, heart failure, pericarditis or other 
cardiovascular disorder?, If “yes”, information on diagnosis year and treatment 
institute were established with the following question: ”in what year was it diagnosed 
and what and where was the treatment?”. In order to validate the self-reported heart 
failure data, we extracted heart failure information from the medical records for all 
CCS with potentially heart failure. We used an extraction-flowchart method especially 
developed for consistent and valid grading (see Figure S2).1 This method consists of 
an extraction form and a set of flowcharts for specific cardiac conditions which allows 
grading of the heart failure according to the CTCAEv3.0 and v4.0.1  
We defined grading of heart failure as follows: grade 3 (severe), grade 4 (life-
threatening or disabling) or grade 5 (fatal).1 We considered the date on which a 
symptomatic heart failure was first confirmed by diagnostic testing as the cardiac 
incidence date. We included heart failures occurring after the 5-year survival date 
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and were still on-going after 5-year survival: the incidence date is then set on 5 years 














Around 17% of the CCS reported potential heart failure (n=484) in the DCOG-LATER 
questionnaire. We were able to validate almost all of them (n=474; 97.9%) and we 
graded by extracting relevant data on the potential heart failure from their DCOG-
LATER hospital medical chart, from their GP or other hospital records. However, 10 
(2.1%) CCS did not give permission to request information from their GP or other 
hospital and we were unable to extract sufficient information from their medical notes 
at the DCOG-LATER hospital. Nevertheless, we were able to establish the nature 
and grade of the potential CE for these CCS, by the information they provided on the 
DCOG-LATER questionnaire. Of the 484 CCS who reported a cardiac event (CE) in 
the DCOG-LATER questionnaire, 58 (11.8%) CCS had a symptomatic heart failure 
and were therefore included in the study as a cardiac case. Six percent (n=46) of the 
GPs reported a potential CE in the GP DCOG-LATER questionnaire. All of them 
could be validated and graded by extracting relevant data from their medical chart. Of 
the GPs who reported a potential CE in the GP DCOG-LATER questionnaire, we 
found that 6 (13.0%) CCS had a symptomatic heart failure and were therefore 
included in the study as a cardiac case. From the DCOG-LATER outpatient clinics we 
found 7.9% (n=161) CCS who had a potential CE. All of the potential CEs could be 
validated and graded by extracting relevant data about the potential CE from their 
cardiology medical chart. In 52 (32.3%) CCS the heart failure was symptomatic and 
these patients were therefore included in the study as a cardiac case. In order to 
assess completeness of reporting, we randomly collected 20 CCS who did not report 
a potential CE and validated this by extracting data from their medical records, none 
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Table S1. Cumulative incidence of heart failure (≥ grade 3) over time since diagnosis (follow-up) in childhood cancer 
survivors according to the nonparametric estimator of cause-specific cumulative incidence, with death from any cause 
as competing risk. 
Treatment groups   
follow-up 
10 yr 
95% CI   
follow-
up 20 yr 
95% CI   
follow-
up 30 yr 
95% CI   
follow-
up 40 yr 
95% CI 
 
Overall   0.4% 0.2-0.5   1.3% 1.0-1.7   3.0% 2.3-3.6   4.4% 3.4-5.5  
Cardiotoxic treatment yes/no              
No cardiotoxic treatment*   0.0% 0.0-0.0   0.0% 0.0-0.0   0.1% 0.0-0.3   0.3% 0.0-0.7  
Cardiotoxic treatment†   0.7% 0.41-1.0   2.6% 2.0-3.3   6.3% 4.9-7.7   10.6% 7.4-13.9  
Types of cardiotoxic treatment              
Cardotoxic CT only   0.8% 0.4-1.1   2.8% 2.1-3.6   6.4% 4.7-8.1   10.5% 6.6-14.4  
Chest RT only   0.5% 0.0-1.4   0.5% 0.0-1.5   1.2% 0.00-3.0   3.0% 0.0-5.9  
Cardiotox CT and chest RT   0.5% 0.0-1.1   2.5% 0.8-4.2   9.6% 5.13-14.12   27.8% 5.1-50.6  
Types of cardiotoxic chemotherapy              
     Mitoxantrone (+/-anthracyclines)   1.5% 0.1-3.5   11.4% 3.6-19.1   16.9% 4.1-29.7   16.9% 4.1-29.7  
1-100 mg/m2 anthracycline‡   0.2% 0.1-0.7   0.7% 0.0-1.7   1.2% 0.0-2.7   1.2% 0.0-2.7  
100-250 mg/m2 anthracycline‡    0.5% 0.1-0.8   1.4% 0.7-2.2   4.0% 1.8-6.2   37.3% 0.0-87.5  
>250 mg/m2 anthracycline‡   1.2% 0.4-2.0   5.2% 3.4-7.1   13.0% 9.4-16.6   24.3% 15.3-33.3  
Period of treatment              
1970-1979   0.2% 0.0-0.5   0.5% 0.0-0.9   1.4% 0.6-2.2   2.9% 1.7-4.2  
1980-1989   0.4% 0.1-0.7   1.6% 1.0-2.2   3.9% 2.8-4.9   xx xx  
1990-2001   0.4% 0.2-0.6   1.5% 0.9-2.0   xx xx   xx xx  
 * No cardiotoxic treatment defined as treated without anthracyclines, mitoxantrone and radiotherapy involving the heart   
 † Cardiotoxic treatment defined as treated with anthracyclines, mitoxantrone and/ or radiotherapy involving the heart  
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Table S2. Cumulative incidence of heart failure (≥ grade 3) at attained age in childhood cancer survivors according to the 
nonparametric estimator of the cause-specific cumulative incidence, with death from any other cause as competing risk. 





















Overall   0.2% 0.0-0.4 0.8% 0.5-1.1   2.0% 1.6-2.5 3.7% 2.9-4.4 5.3% 3.7-6.9 
Cardiotoxic treatment yes/no             
No cardiotoxic treatment†   0.0% 0.0-0.0 0.0% 0.0-0.0   0.1% 0.0-0.1 0.3% 0.0-0.6 0.3% 0.06-0.6 
Cardiotoxic treatment◊   0.5% 0.0-0.9 1.7% 1.1-2.3   4.0% 3.1-4.9 7.3% 5.6-8.9 11.6% 7.4-15.8 
Types of cardiotoxic treatment             
Cardotoxic CT only   0.3% 0.0-0.6 1.5% 0.9-2.1   3.9% 2.9-4.9 6.4% 4.7-8.2 11.6% 7.1-16.1 
Chest RT only   0.0% 0.0-0.0 0.0% 0.0-0.0   0.5% 0.0-1.5 2.6% 0.0-5.1 2.6% 0.0-5.1 
Cardiotox CT and chest RT   2.9% 0.0-7.4 4.7% 0.0-9.3   7.4% 2.5-12.2 14.6% 7.4-21.7 33.2% 2.8-63.7 
Types of cardiotoxic chemotherapy             
        Mitoxantrone (+/anthracyclines)   0.0% 0.0-0.0 0.3% 0.2-0.7   0.6% 0.0-1.4 1.2% 0.0-2.7 1.2% 0.0-2.7 
1-100 mg/m2 anthracycline*   0.3% 0.0-0.6 0.8% 0.3-1.4   2.3% 1.3-3.4 4.5% 1.9-7.0 18.3% 0.0-43.3 
100-250 mg/m2 anthracycline*    0.4% 0.0-1.1 3.0% 1.5-4.6   7.0% 4.8-9.2 13.0% 9.3-16.7 19.2% 12.7-25.8 
>250 mg/m2 anthracycline*   0.0% 0.0-0.0 4.1% 0.6-7.7   12.9% 5.5-20.3 12.9% 5.5-20.3 12.9% 5.5-20.3 
† No cardiotoxic treatment defined as treated without anthracyclines, mitoxantrone and radiotherapy involving the 
heart  
◊ Cardiotoxic treatment defined as treated with anthracyclines, mitoxantrone and/ or radiotherapy involving the 
heart  
* Without mitoxantrone 
CT= chemotherapy (anthracyclines and mitoxantrone) 
Chest RT =radiotherapy involving the heart  
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Figure S1. Flowchart of the cardiac data collection.   
 
 
Qx= Questionnaire, LATER= Long term Effects after Childhood Cancer   
* CCS were who living abroad, were in active cancer treatment or could not be traced 
at the time of follow-up 
  # CCS who did not participate in the LATER questionnaire, and did not give 
permission for GP questionnaire  
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Figure S3. Cumulative incidence of heart failure at time since childhood cancer 
diagnosis for four mutually exclusive treatment groups.  
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Figure S4. Cumulative incidence of heart failure at attained age for cardiotoxic 
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